| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Medicine, Cardiovascular Division, and Department of Pharmacology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, 19104, USA; and
* Department of Immunology and Cell Biology, Scripps Research Institute, La Jolla, California 92037, USA
1Correspondence: University of Pennsylvania Medical Center, Room 956, BRBII/III, 421 Curie BLVD, Philadelphia, PA 19104, USA. E-mail: liangb{at}mail.med.upenn.edu
Adenosine exerts a potent cardioprotective effect that is mediated by adenosine A1 and A3 receptors. The signaling pathways activated by the A1 and A3 receptors are distinct and involve selective coupling to phospholipases C and D, respectively. The objective of our study was to elucidate the signaling mechanism that mediates the coupling of each receptor to its respective phospholipase and to test the role of RhoA as a novel mediator leading from adenosine receptors to cardioprotection. C3 transferase and dominant negative RhoA (RhoAT19N) blocked the A3 receptor-mediated phospholipase D activation and cardioprotection but had no effect on A1 receptor-mediated phospholipase C activation or cardioprotection. In contrast, pertussis toxin treatment caused a greater inhibition of the diacylglycerol accumulation induced by the A1 agonist than by the A3 agonist, and it completely abrogated the A1 agonist-mediated cardioprotection. Thus, adenosine A1 and A3 receptors are linked to different G-proteins. The A3 receptor is coupled via RhoA to activate phospholipase D in exerting its cardioprotective effect, whereas the A1 receptor is linked via Gi to phospholipase C to produce cardioprotective responses. The present study identifies a novel role for RhoA and further suggests its importance in regulating cardiac cellular function.—Lee, J. E., Bokoch, G., and Liang, B. T. A novel cardioprotective role of RhoA: new signaling mechanism for adenosine.
Key Words: myocytes • ischemia • cytoprotection • phospholipase D • monomeric G-protein
This article has been cited by other articles:
|
|
 |
|
  A. D.T. Costa, S. V. Pierre, M. V. Cohen, J. M. Downey, and K. D. Garlid cGMP signalling in pre- and post-conditioning: the role of mitochondria Cardiovasc Res, January 15, 2008; 77(2): 344 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. R. Tracey, W. P. Magee, J. J. Oleynek, R. J. Hill, A. H. Smith, D. M. Flynn, and D. R. Knight Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2780 - H2787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Headrick, B. Hack, and K. J. Ashton Acute adenosinergic cardioprotection in ischemic-reperfused hearts Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H1797 - H1818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Feoktistov, S. Ryzhov, A. E. Goldstein, and I. Biaggioni Mast Cell-Mediated Stimulation of Angiogenesis: Cooperative Interaction Between A2B and A3 Adenosine Receptors Circ. Res., March 21, 2003; 92(5): 485 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Black Jr, Y. Guo, Z.-D. Ge, S. S. Murphree, S. D. Prabhu, W. K. Jones, R. Bolli, and J. A. Auchampach Gene Dosage-Dependent Effects of Cardiac-Specific Overexpression of the A3 Adenosine Receptor Circ. Res., July 26, 2002; 91(2): 165 - 172. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
